Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases

Joon Seong Park, Dong Hwan Kim, Chul Won Choi, Seong Hyun Jeong, Jin Hyuk Choi, Kihyun Kim, Seok Jin Kim, Chul Won Jung, Deok Hwan Yang, Jun Ho Jang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients. Methods: Micafungin was administered for sustained fever (>38.4°C) on days 3-5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. Results: A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7% (29/47). A total of 3 patients (6.4%) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21%) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients (<50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≥0.05 × 109/l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. Conclusion: Micafungin has an excellent efficacy (61.7%) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalActa Haematologica
Volume124
Issue number2
DOIs
Publication statusPublished - 2010 Oct

Keywords

  • Hematological diseases
  • Micafungin
  • Neutropenic fever

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases'. Together they form a unique fingerprint.

  • Cite this

    Park, J. S., Kim, D. H., Choi, C. W., Jeong, S. H., Choi, J. H., Kim, K., Kim, S. J., Jung, C. W., Yang, D. H., & Jang, J. H. (2010). Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Acta Haematologica, 124(2), 92-97. https://doi.org/10.1159/000315558